قالب وردپرس درنا توس
Home / Health / 6 updates to World Head and Neck Day

6 updates to World Head and Neck Day



Today is the third annual World Day of Head and Neck Cancer, a day that brings together doctors, patients and policymakers to raise awareness of the disease and recent treatment advances.

Head and neck cancers will account for nearly 65,000 new cancers diagnosed in the United States this year, causing more than 13,000 deaths, according to the American Cancer Society.

In Honor of World Head and Neck Today HemOnc Today compiled a list of six updates in the field of head and neck cancer, including new research into immunotherapeutics and symptom monitoring strategies.

  • Immunotherapeutics have had dramatic effects on a variety of cancers, including head and neck cancer. Two researchers discuss this "paradigm shift" treatment. CONTINUE READING.
  • Neoadjuvant chemotherapy and surgery followed by risk-adjusted adjuvant therapy resulted in "excellent" results in patients with squamous cell carcinoma of the head and neck. CONTINUE READING.
  • Women seemed less likely than men to receive intensive treatment for head and neck cancer. When researchers controlled factors such as age and serious medical conditions, their analysis showed that the ratio of cancer mortality to non-cancer mortality in women was twice that of men. READ MORE
  • Patients with head and neck cancer who were remotely monitored by a mobile app and sensor technology had less severe symptoms than patients who had weekly visits to the doctor. CONTINUE READING.
  • The median age of patients with squamous cell carcinoma of the HPV-related oropharynx has increased since 1
    995, reflecting the increasing incidence in older adults. Regardless of age, patients with HPV-related oropharyngeal squamous cell carcinoma showed improved OS compared to patients with HPV-unrelated tumors. READ MORE
  • Researchers from the Atlantic HPV Center at the Leonard B. Kahn Head and Neck Cancer Institute are studying an experimental HPV vaccine and treatment with the PD-L1 inhibitor Durvalumab (Imfinzi, AstraZeneca) in a cohort of Patients with HPV-associated head and neck carcinomas. READ MORE.


Source link